Reuters - Strive Pharmacy said on Tuesday it has no plans to resume sales of a compounded version of Novo Nordisk's (NOVOb.CO)
, opens new tab
oral semaglutide, ‌pushing back on an earlier media report that it would reintroduce the GLP-1 pill, which was pulled from the market after U.S. regulators raised concerns.
The Arizona-based compounding pharmacy said its pill technology could be used with several active ingredients, including semaglutide.

Strive was the compounding pharmacy ‌behind ⁠Hims' compounded semaglutide pill.

FDA Moves to Permanently Close the Door on Compounded GLP-1s

The FDA has announced that it is proposing to formally exclude semaglutide (Ozempic, Wegovy; Novo Nordisk), tirzepatide (Mounjaro, Zepbound; Eli Lilly and Company), and liraglutide (Victoza, Saxenda; Novo Nordisk) from the 503B outsourcing facility bulk drug substances (bulks) list—the regulatory mechanism that governs which active pharmaceutical ingredients large-scale compounding operations may use. If finalized, the rule would prohibit 503B outsourcing facilities from compounding these agents from bulk substances under any circumstances, regardless of future market conditions.^(1)